Mark Baldry - 03 Nov 2022 Form 4 Insider Report for X4 Pharmaceuticals, Inc (XFOR)

Role
Chief Commercial Officer
Signature
/s/ Adam S. Mostafa, attorney-in-fact
Issuer symbol
XFOR
Transactions as of
03 Nov 2022
Net transactions value
+$644,490
Form type
4
Filing time
04 Nov 2022, 16:18:11 UTC
Next filing
02 Nov 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XFOR Stock Option (right to buy) Award $644,490 +341,000 $1.89 341,000 03 Nov 2022 Common Stock 341,000 $1.89 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option shall vest on November 3, 2023, with the remainder vesting in equal installments of 2.0833% of the shares subject to the option each successive month thereafter for a period of 36 months, subject to the Reporting Person continuing to provide services through each such date.